Comment on "Fibroblasts in Nodular SclerosingClassical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury" Cancers 2019, 11, 1687.

We read with great interest the recent publication by Bankov et al. where they described the characteristics and functional activity of fibroblasts in Nodular Sclerosis (NS) Classical Hodgkin Lymphoma (cHL) [1]. The authors compared the gene expression and methylation profiles of fibroblasts isolated from primary lymph node suspensions and from lymphadenitis, founding significant differences, including a down regulation of the IL-7R gene and a strong up regulation of tissue inhibitor of metalloproteinase 3 (TIMP3). The authors reported that conditioned medium from Hodgkin and Reed Sternberg (HRS) tumor cells increased NS cHL fibroblast proliferation and that tumor cells were protected against the cytotoxic effects of Brentuximab-Vedotin by cHLfibroblasts [1]. [...].